Anadys begins dosing in hepatitis drug study
The study will evaluate ANA598, the company’s direct-acting antiviral, in both treatment-naive patients and patients who have failed a prior course of HCV therapy with interferon and ribavirin.
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.